Loading…
Lenalidomide in treatment-refractory cutaneous lupus erythematosus: Efficacy and safety in a 52-week trial
Saved in:
| Published in: | Journal of the American Academy of Dermatology 2014-03, Vol.70 (3), p.583-584 |
|---|---|
| Main Authors: | , , , , , , |
| Format: | Article |
| Language: | English |
| Subjects: | |
| Citations: | Items that this one cites Items that cite this one |
| Online Access: | Get full text |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| cited_by | cdi_FETCH-LOGICAL-c510t-d218a7a8a40e2aeec7427287571309c213e82a0614e274e52efa8a01116893203 |
|---|---|
| cites | cdi_FETCH-LOGICAL-c510t-d218a7a8a40e2aeec7427287571309c213e82a0614e274e52efa8a01116893203 |
| container_end_page | 584 |
| container_issue | 3 |
| container_start_page | 583 |
| container_title | Journal of the American Academy of Dermatology |
| container_volume | 70 |
| creator | Okon, Lauren, MD Rosenbach, Misha, MD Krathen, Michael, MD Rose, Mathew, MS Propert, Kathleen, ScD Okawa, Joyce, RN Werth, Victoria, MD |
| description | |
| doi_str_mv | 10.1016/j.jaad.2013.11.007 |
| format | article |
| fullrecord | <record><control><sourceid>elsevier_pubme</sourceid><recordid>TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_4333148</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>S0190962213012620</els_id><sourcerecordid>S0190962213012620</sourcerecordid><originalsourceid>FETCH-LOGICAL-c510t-d218a7a8a40e2aeec7427287571309c213e82a0614e274e52efa8a01116893203</originalsourceid><addsrcrecordid>eNp9kctu1TAQhi1ERU8LL8AC5QUSZpyLE4QqoapQpCN10bK2BmdCneZyZDut8vY4OlABCzb2wv__WfONEG8RMgSs3vdZT9RmEjDPEDMA9ULsEBqVVqpWL8UOsIG0qaQ8FWfe9wDQFLl6JU5lUcq6AbUT_Z4nGmw7j7blxE5JcExh5CmkjjtHJsxuTcwSaOJ58cmwHOLJbg33PFKY_eI_JFddZw2ZNaGpTTx1HNYNRUkp0yfmhwi1NLwWJx0Nnt_8us_Ft89Xd5fX6f7my9fLT_vUlAghbSXWpKimAlgSs1GFVLJWpcIcGiMx51oSVFiwVAWXkrsYBkSs6iaXkJ-LiyP3sHwfuTVxFkeDPjg7klv1TFb__TLZe_1jftRFnudY1BEgjwDjZu-jhucugt7M615v5vVmXiPqaD6W3v3563Plt-oY-HgMcJz90bLT3lieDLfWsQm6ne3_-Rf_1M1gp6h9eOCVfT8vLi7Sa9ReatC32-631UdpKKuo5Sdocqst</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype></control><display><type>article</type><title>Lenalidomide in treatment-refractory cutaneous lupus erythematosus: Efficacy and safety in a 52-week trial</title><source>ScienceDirect Freedom Collection</source><creator>Okon, Lauren, MD ; Rosenbach, Misha, MD ; Krathen, Michael, MD ; Rose, Mathew, MS ; Propert, Kathleen, ScD ; Okawa, Joyce, RN ; Werth, Victoria, MD</creator><creatorcontrib>Okon, Lauren, MD ; Rosenbach, Misha, MD ; Krathen, Michael, MD ; Rose, Mathew, MS ; Propert, Kathleen, ScD ; Okawa, Joyce, RN ; Werth, Victoria, MD</creatorcontrib><identifier>ISSN: 0190-9622</identifier><identifier>EISSN: 1097-6787</identifier><identifier>DOI: 10.1016/j.jaad.2013.11.007</identifier><identifier>PMID: 24528907</identifier><language>eng</language><publisher>United States: Elsevier Inc</publisher><subject>Administration, Oral ; Biopsy, Needle ; Dermatology ; Dose-Response Relationship, Drug ; Drug Administration Schedule ; Female ; Follow-Up Studies ; Humans ; Immunohistochemistry ; Lupus Erythematosus, Cutaneous - drug therapy ; Lupus Erythematosus, Cutaneous - pathology ; Male ; Patient Safety ; Prospective Studies ; Severity of Illness Index ; Thalidomide - analogs & derivatives ; Thalidomide - therapeutic use ; Time Factors ; Treatment Outcome</subject><ispartof>Journal of the American Academy of Dermatology, 2014-03, Vol.70 (3), p.583-584</ispartof><rights>American Academy of Dermatology, Inc.</rights><rights>2013 American Academy of Dermatology, Inc.</rights><rights>2013 American Academy of Dermatology, Inc. Published by Mosby, Inc. All rights reserved. 2013</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c510t-d218a7a8a40e2aeec7427287571309c213e82a0614e274e52efa8a01116893203</citedby><cites>FETCH-LOGICAL-c510t-d218a7a8a40e2aeec7427287571309c213e82a0614e274e52efa8a01116893203</cites><orcidid>0000-0002-8154-4258</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>230,314,780,784,885,27924,27925</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/24528907$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Okon, Lauren, MD</creatorcontrib><creatorcontrib>Rosenbach, Misha, MD</creatorcontrib><creatorcontrib>Krathen, Michael, MD</creatorcontrib><creatorcontrib>Rose, Mathew, MS</creatorcontrib><creatorcontrib>Propert, Kathleen, ScD</creatorcontrib><creatorcontrib>Okawa, Joyce, RN</creatorcontrib><creatorcontrib>Werth, Victoria, MD</creatorcontrib><title>Lenalidomide in treatment-refractory cutaneous lupus erythematosus: Efficacy and safety in a 52-week trial</title><title>Journal of the American Academy of Dermatology</title><addtitle>J Am Acad Dermatol</addtitle><subject>Administration, Oral</subject><subject>Biopsy, Needle</subject><subject>Dermatology</subject><subject>Dose-Response Relationship, Drug</subject><subject>Drug Administration Schedule</subject><subject>Female</subject><subject>Follow-Up Studies</subject><subject>Humans</subject><subject>Immunohistochemistry</subject><subject>Lupus Erythematosus, Cutaneous - drug therapy</subject><subject>Lupus Erythematosus, Cutaneous - pathology</subject><subject>Male</subject><subject>Patient Safety</subject><subject>Prospective Studies</subject><subject>Severity of Illness Index</subject><subject>Thalidomide - analogs & derivatives</subject><subject>Thalidomide - therapeutic use</subject><subject>Time Factors</subject><subject>Treatment Outcome</subject><issn>0190-9622</issn><issn>1097-6787</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2014</creationdate><recordtype>article</recordtype><recordid>eNp9kctu1TAQhi1ERU8LL8AC5QUSZpyLE4QqoapQpCN10bK2BmdCneZyZDut8vY4OlABCzb2wv__WfONEG8RMgSs3vdZT9RmEjDPEDMA9ULsEBqVVqpWL8UOsIG0qaQ8FWfe9wDQFLl6JU5lUcq6AbUT_Z4nGmw7j7blxE5JcExh5CmkjjtHJsxuTcwSaOJ58cmwHOLJbg33PFKY_eI_JFddZw2ZNaGpTTx1HNYNRUkp0yfmhwi1NLwWJx0Nnt_8us_Ft89Xd5fX6f7my9fLT_vUlAghbSXWpKimAlgSs1GFVLJWpcIcGiMx51oSVFiwVAWXkrsYBkSs6iaXkJ-LiyP3sHwfuTVxFkeDPjg7klv1TFb__TLZe_1jftRFnudY1BEgjwDjZu-jhucugt7M615v5vVmXiPqaD6W3v3563Plt-oY-HgMcJz90bLT3lieDLfWsQm6ne3_-Rf_1M1gp6h9eOCVfT8vLi7Sa9ReatC32-631UdpKKuo5Sdocqst</recordid><startdate>20140301</startdate><enddate>20140301</enddate><creator>Okon, Lauren, MD</creator><creator>Rosenbach, Misha, MD</creator><creator>Krathen, Michael, MD</creator><creator>Rose, Mathew, MS</creator><creator>Propert, Kathleen, ScD</creator><creator>Okawa, Joyce, RN</creator><creator>Werth, Victoria, MD</creator><general>Elsevier Inc</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>5PM</scope><orcidid>https://orcid.org/0000-0002-8154-4258</orcidid></search><sort><creationdate>20140301</creationdate><title>Lenalidomide in treatment-refractory cutaneous lupus erythematosus: Efficacy and safety in a 52-week trial</title><author>Okon, Lauren, MD ; Rosenbach, Misha, MD ; Krathen, Michael, MD ; Rose, Mathew, MS ; Propert, Kathleen, ScD ; Okawa, Joyce, RN ; Werth, Victoria, MD</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c510t-d218a7a8a40e2aeec7427287571309c213e82a0614e274e52efa8a01116893203</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2014</creationdate><topic>Administration, Oral</topic><topic>Biopsy, Needle</topic><topic>Dermatology</topic><topic>Dose-Response Relationship, Drug</topic><topic>Drug Administration Schedule</topic><topic>Female</topic><topic>Follow-Up Studies</topic><topic>Humans</topic><topic>Immunohistochemistry</topic><topic>Lupus Erythematosus, Cutaneous - drug therapy</topic><topic>Lupus Erythematosus, Cutaneous - pathology</topic><topic>Male</topic><topic>Patient Safety</topic><topic>Prospective Studies</topic><topic>Severity of Illness Index</topic><topic>Thalidomide - analogs & derivatives</topic><topic>Thalidomide - therapeutic use</topic><topic>Time Factors</topic><topic>Treatment Outcome</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Okon, Lauren, MD</creatorcontrib><creatorcontrib>Rosenbach, Misha, MD</creatorcontrib><creatorcontrib>Krathen, Michael, MD</creatorcontrib><creatorcontrib>Rose, Mathew, MS</creatorcontrib><creatorcontrib>Propert, Kathleen, ScD</creatorcontrib><creatorcontrib>Okawa, Joyce, RN</creatorcontrib><creatorcontrib>Werth, Victoria, MD</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>Journal of the American Academy of Dermatology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Okon, Lauren, MD</au><au>Rosenbach, Misha, MD</au><au>Krathen, Michael, MD</au><au>Rose, Mathew, MS</au><au>Propert, Kathleen, ScD</au><au>Okawa, Joyce, RN</au><au>Werth, Victoria, MD</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Lenalidomide in treatment-refractory cutaneous lupus erythematosus: Efficacy and safety in a 52-week trial</atitle><jtitle>Journal of the American Academy of Dermatology</jtitle><addtitle>J Am Acad Dermatol</addtitle><date>2014-03-01</date><risdate>2014</risdate><volume>70</volume><issue>3</issue><spage>583</spage><epage>584</epage><pages>583-584</pages><issn>0190-9622</issn><eissn>1097-6787</eissn><cop>United States</cop><pub>Elsevier Inc</pub><pmid>24528907</pmid><doi>10.1016/j.jaad.2013.11.007</doi><tpages>2</tpages><orcidid>https://orcid.org/0000-0002-8154-4258</orcidid><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0190-9622 |
| ispartof | Journal of the American Academy of Dermatology, 2014-03, Vol.70 (3), p.583-584 |
| issn | 0190-9622 1097-6787 |
| language | eng |
| recordid | cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_4333148 |
| source | ScienceDirect Freedom Collection |
| subjects | Administration, Oral Biopsy, Needle Dermatology Dose-Response Relationship, Drug Drug Administration Schedule Female Follow-Up Studies Humans Immunohistochemistry Lupus Erythematosus, Cutaneous - drug therapy Lupus Erythematosus, Cutaneous - pathology Male Patient Safety Prospective Studies Severity of Illness Index Thalidomide - analogs & derivatives Thalidomide - therapeutic use Time Factors Treatment Outcome |
| title | Lenalidomide in treatment-refractory cutaneous lupus erythematosus: Efficacy and safety in a 52-week trial |
| url | http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-06T17%3A19%3A10IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-elsevier_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Lenalidomide%20in%20treatment-refractory%20cutaneous%20lupus%20erythematosus:%20Efficacy%20and%20safety%20in%20a%2052-week%20trial&rft.jtitle=Journal%20of%20the%20American%20Academy%20of%20Dermatology&rft.au=Okon,%20Lauren,%20MD&rft.date=2014-03-01&rft.volume=70&rft.issue=3&rft.spage=583&rft.epage=584&rft.pages=583-584&rft.issn=0190-9622&rft.eissn=1097-6787&rft_id=info:doi/10.1016/j.jaad.2013.11.007&rft_dat=%3Celsevier_pubme%3ES0190962213012620%3C/elsevier_pubme%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-c510t-d218a7a8a40e2aeec7427287571309c213e82a0614e274e52efa8a01116893203%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_id=info:pmid/24528907&rfr_iscdi=true |